kabutan

OncoTherapy Science, Inc.(4564) Summary

4564
TSE Growth
OncoTherapy Science, Inc.
21
JPY
-1
(-4.55%)
Dec 12, 3:30 pm JST
0.13
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
21
Dec 12, 11:46 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.59
Yield
ー%
Margin Trading Ratio
4.45
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
21 JPY 0.13 USD
Previous Close Dec 11
22 JPY 0.14 USD
High Dec 12, 9:03 am
22 JPY 0.14 USD
Low Dec 12, 9:39 am
20 JPY 0.12 USD
Volume
102,910,800
Trading Value
2.16B JPY 0.01B USD
VWAP
21.0 JPY 0.14 USD
Minimum Trading Value
2,100 JPY 13 USD
Market Cap
7.22B JPY 0.05B USD
Number of Trades
285
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
248
1-Year High Jun 30, 2025
2,195
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 11,772,200 19,258,700 1.64
Nov 28, 2025 10,467,900 17,904,100 1.71
Nov 21, 2025 10,046,400 18,777,800 1.87
Nov 14, 2025 2,043,100 17,348,200 8.49
Nov 7, 2025 1,596,600 17,629,700 11.04
Company Profile
OncoTherapy Science, Inc. is a drug discovery venture originating from the Institute of Medical Science at the University of Tokyo. The company's main focus is on cancer gene analysis and the development of cancer therapeutics.
Sector
Pharmaceuticals
OncoTherapy Science, Inc. is a research and development-oriented venture that broadly engages in cancer drug development, from drug discovery research to clinical trials. The company promotes R&D in various areas including small molecule drugs, cancer peptide vaccines, and antibody drugs, with multiple ongoing clinical trials. Through its subsidiary, OncoTherapy Science also conducts large-scale cancer gene analysis tests and research and development of cancer immunotherapy, thus engaging in cancer precision medicine-related businesses. The company aims to realize personalized medicine through these efforts. OncoTherapy Science has established a staged revenue model including upfront payments, milestones, and royalties through partnerships with major pharmaceutical companies. The company is characterized by its long-term approach to research and development. As a result, its financial performance largely depends on the development progress of partnering pharmaceutical companies and the sales status of pharmaceuticals, which may not be reflected in short-term results in many cases.